1. Home
  2. NKSH vs CABA Comparison

NKSH vs CABA Comparison

Compare NKSH & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKSH

National Bankshares Inc.

HOLD

Current Price

$38.41

Market Cap

243.3M

Sector

Finance

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.91

Market Cap

212.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKSH
CABA
Founded
1891
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.3M
212.7M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
NKSH
CABA
Price
$38.41
$2.91
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
12.4K
3.2M
Earning Date
04-23-2026
01-01-0001
Dividend Yield
3.96%
N/A
EPS Growth
N/A
N/A
EPS
1.56
N/A
Revenue
$7,474,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.62
N/A
Revenue Growth
5.68
N/A
52 Week Low
$23.75
$0.99
52 Week High
$40.00
$3.67

Technical Indicators

Market Signals
Indicator
NKSH
CABA
Relative Strength Index (RSI) 68.65 63.44
Support Level $37.54 $2.29
Resistance Level $38.72 $3.26
Average True Range (ATR) 0.83 0.20
MACD -0.13 0.05
Stochastic Oscillator 53.67 83.42

Price Performance

Historical Comparison
NKSH
CABA

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: